Predicting Dropout Rates In DCTs

In phase 3 trials, the stakes are high. Not only do sponsors need to prove safety and efficacy, but they need to have a sufficiently robust study population for their outcomes to be statistically significant. Enrollment is important; retention is essential; decentralized trials (DCTs) may add complexity due to the lack of interaction between patient and trial personnel.

Our client was in the midst of a phase 3 trial for their lead drug, with 1350 patients at 250 sites across the United States. They came to us asking for help identifying those patients most in danger of discontinuing, so our client could take action to retain those at risk—attaining a high subject retention rate and reaping all the downstream benefits of low subject discontinuations.